Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...

The BioNTech SE ADR BNTX rallied 1.00% to $124.71 Tuesday, on what proved to be an all-around mixed trading session for the ...

BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The ...

The BioNTech SE ADR BNTX inched 0.06% higher to $123.47 Monday, on what proved to be an all-around great trading session for ...

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.

BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...